Julie A. Johnson

1983–2025 年に発表

136
論文数
20,413
被引用数
82
h 指数
127
i10 指数

被引用数

Julie A. Johnson の年別被引用数1969 年: 被引用 2 件1984 年: 被引用 15 件1985 年: 被引用 21 件1986 年: 被引用 37 件1987 年: 被引用 37 件1988 年: 被引用 28 件1989 年: 被引用 26 件1990 年: 被引用 36 件1991 年: 被引用 27 件1992 年: 被引用 13 件1993 年: 被引用 18 件1994 年: 被引用 13 件1995 年: 被引用 12 件1996 年: 被引用 12 件1997 年: 被引用 22 件1998 年: 被引用 18 件1999 年: 被引用 16 件2000 年: 被引用 16 件2001 年: 被引用 23 件2002 年: 被引用 24 件2003 年: 被引用 33 件2004 年: 被引用 61 件2005 年: 被引用 69 件2006 年: 被引用 125 件2007 年: 被引用 98 件2008 年: 被引用 95 件2009 年: 被引用 105 件2010 年: 被引用 109 件2011 年: 被引用 116 件2012 年: 被引用 99 件2013 年: 被引用 136 件2014 年: 被引用 165 件2015 年: 被引用 104 件2016 年: 被引用 134 件2017 年: 被引用 166 件2018 年: 被引用 160 件2019 年: 被引用 612 件2020 年: 被引用 607 件2021 年: 被引用 689 件2022 年: 被引用 500 件2023 年: 被引用 357 件2024 年: 被引用 603 件2025 年: 被引用 236 件2026 年: 被引用 10 件1970〜1983 年は被引用が無いため表示していません

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 2,041 件、この内訳の 26.9%イギリス: 引用元論文 753 件、この内訳の 9.9%中国: 引用元論文 604 件、この内訳の 8%ドイツ: 引用元論文 350 件、この内訳の 4.6%カナダ: 引用元論文 277 件、この内訳の 3.6%オランダ: 引用元論文 260 件、この内訳の 3.4%スウェーデン: 引用元論文 250 件、この内訳の 3.3%イタリア: 引用元論文 213 件、この内訳の 2.8%オーストラリア: 引用元論文 195 件、この内訳の 2.6%スペイン: 引用元論文 189 件、この内訳の 2.5%日本: 引用元論文 176 件、この内訳の 2.3%フランス: 引用元論文 167 件、この内訳の 2.2%
0%26.9%その他 27.9%

分野

  • Medicine41.4%
  • Biochemistry, Genetics and Molecular Biology28.4%
  • Pharmacology, Toxicology and Pharmaceutics15.9%
  • Neuroscience7%
  • Computer Science1.6%
  • Immunology and Microbiology1.3%
  • その他4.4%

トピック

  • Pharmacogenetics and Drug Metabolism7.1%
  • Genetic Associations and Epidemiology5%
  • Pluripotent Stem Cells Research2.6%
  • Antiplatelet Therapy and Cardiovascular Diseases2.1%
  • CRISPR and Genetic Engineering1.9%
  • Computational Drug Discovery Methods1.7%
  • その他79.6%

共著者

全論文

検索で開く
  1. Multiancestry genome-wide association study of 520,000 subjects identifies 32 loci associated with stroke and stroke subtypes

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Carlos Cruchaga, John Danesh, Paul I. W. de Bakker, Anita L. DeStefano, Marcel den Hoed, Qing Duan, Stefan T. Engelter, Guido J. Falcone, Rebecca F. Gottesman, Raji P. Grewal, Vilmundur Guðnason, Stefan Gustafsson, Jeffrey Haessler, Tamara B. Harris, Ahamad Hassan, Aki S. Havulinna, Susan R. Heckbert, Elizabeth G. Holliday, George Howard, Fang‐Chi Hsu, Hyacinth I. Hyacinth, M. Arfan Ikram, Erik Ingelsson, Marguerite R. Irvin, Xueqiu Jian, Jordi Jiménez‐Conde, Julie A. Johnson, J. Wouter Jukema, Masahiro Kanai, Keith L. Keene, Brett Kissela, Dawn Kleindorfer, Charles Kooperberg, Michiaki Kubo, Leslie A. Lange, Carl D. Langefeld, Claudia Langenberg, Lenore J. Launer, Jin‐Moo Lee, Robin Lemmens, Didier Leys, Cathryn M. Lewis, Wei‐Yu Lin, Arne G. Lindgren, Erik Lorentzen, Patrik K. E. Magnusson, Jane Maguire, Ani Manichaikul, Patrick F. McArdle, James F. Meschia, Braxton D. Mitchell, Thomas H. Mosley, Michael A. Nalls, Toshiharu Ninomiya, Martin O’Donnell, Bruce M. Psaty, Sara L. Pulit, Kristiina Rannikmäe, Alex P. Reiner, Kathryn M. Rexrode, Kenneth Rice, Stephen S. Rich, Paul M. Ridker, Natalia S. Rost, Peter M. Rothwell, Jerome I. Rotter, Tatjana Rundek, Ralph L. Sacco, Saori Sakaue, Michèle M. Sale ほか 328 名 - Nature Genetics 2018 被引用: 1,726

  2. Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2C19 Genotype and Clopidogrel Therapy: 2022 Update

    著者: , , , , , , , , , , , , , , , , - Clinical Pharmacology & Therapeutics 2022 被引用: 458

  3. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing

    著者: , , , , , , , , , , , , , , , , , , , - Clinical Pharmacology & Therapeutics 2020 被引用: 298

  4. Proton pump inhibitors: from CYP2C19 pharmacogenetics to precision medicine

    著者: , , - Expert Opinion on Drug Metabolism & Toxicology 2018 被引用: 254

  5. Multisite Investigation of Outcomes With Implementation of CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Mark D. Kelemen, Yee Ming Lee, Oyunbileg Magvanjav, May E. Montasser, David R. Nelson, Edith A. Nutescu, Devon Nwaba, Ruth E. Pakyz, Kathleen Palmer, Josh F. Peterson, Toni I. Pollin, Alison H. Quinn, Shawn Robinson, Jamie Schub, Todd C. Skaar, D. Max Smith, Vindhya Sriramoju, Petr Starostik, Tomasz Styŝ, James M. Stevenson, Nicholas Varunok, Mark R. Vesely, Dyson T. Wake, Karen E. Weck, Kristin Weitzel, Russell A. Wilke, James H. Willig, Yuqi Zhao, Rolf P. Kreutz, George A. Stouffer, Philip E. Empey, Nita A. Limdi, Alan R. Shuldiner, Almut G. Winterstein, Julie A. Johnson - JACC: Cardiovascular Interventions 2017 被引用: 310

  6. Fifteen new risk loci for coronary artery disease highlight arterial-wall-specific mechanisms

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Ron Do, Daniel J. Rader, Julie A. Johnson, Stanley L. Hazen, Arshed A. Quyyumi, John A. Spertus, Carl J. Pepine, Nora Franceschini, Anne E. Justice, Alex P. Reiner, Steven Buyske, Lucia A. Hindorff, Cara L. Carty, Kari E. North, Charles Kooperberg, Eric Boerwinkle, Kristin L. Young, Mariaelisa Graff, Ulrike Peters, Devin Absher, Chao A. Hsiung, Wen‐Jane Lee, Kent D. Taylor, Ying-Hsiang Chen, I‐Te Lee, Xiuqing Guo, Ren‐Hua Chung, Yi‐Jen Hung, Jerome I. Rotter, Jyh‐Ming Jimmy Juang, Thomas Quertermous, Tzung‐Dau Wang, Asif Rasheed, Philippe Frossard, Dewan S Alam, Abdulla al Shafi Majumder, Emanuele Di Angelantonio, Rajiv Chowdhury, Yii‐Der Ida Chen, Børge G. Nordestgaard, Themistocles L. Assimes, John Danesh, Adam S. Butterworth, Danish Saleheen - Nature Genetics 2017 被引用: 322

  7. Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C19 Genotype and Clopidogrel Therapy: 2013 Update

    著者: , , , , , , , , , - Clinical Pharmacology & Therapeutics 2013 被引用: 966

  8. How to Integrate CYP2D6 Phenoconversion Into Clinical Pharmacogenetics: A Tutorial

    著者: , , , , , , , , , - Clinical Pharmacology & Therapeutics 2021 被引用: 89

  9. CYP2C19 Genotype‐Guided Antiplatelet Therapy After Percutaneous Coronary Intervention in Diverse Clinical Settings

    著者: , , , , , , , , , , , , , , , , , , , , , , , , - Journal of the American Heart Association 2022 被引用: 73

  10. Genetically determined NLRP3 inflammasome activation associates with systemic inflammation and cardiovascular mortality

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Jaana Hartiala, W.H. Wilson Tang, Stanley L. Hazen, Hooman Allayee, Caitrin W. McDonough, Yan Gong, Rhonda M. Cooper‐DeHoff, Julie A. Johnson, Markus Scholz, Andrej Teren, Ralph Burkhardt, Andreas Martinsson, J. G. Smith, Lars Wallentin, Stefan James, Niclas Eriksson, Harvey D. White, Claes Held, Dawn Waterworth, Stella Trompet, J. Wouter Jukema, Ian Ford, David J. Stott, Naveed Sattar, Sharon Cresci, John A. Spertus, Hannah Campbell, Sascha Tierling, Jörn Walter, Emmanuel Ampofo, Barbara A. Niemeyer, Peter Lipp, Heribert Schunkert, Michael Böhm, Wolfgang Köenig, Danilo Fliser, Ulrich Laufs, Thimoteus Speer - European Heart Journal 2021 被引用: 92

  11. A Pharmacogenetic versus a Clinical Algorithm for Warfarin Dosing

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Jonas H. Ellenberg - New England Journal of Medicine 2013 被引用: 749

  12. Multisite Investigation of Strategies for the Implementation of CYP2C19 Genotype‐Guided Antiplatelet Therapy

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , - Clinical Pharmacology & Therapeutics 2017 被引用: 127

  13. CYP2D6 pharmacogenetics and phenoconversion in personalized medicine

    著者: , - Expert Opinion on Drug Metabolism & Toxicology 2022 被引用: 64

  14. Recurrent gain of chromosomes 17q and 12 in cultured human embryonic stem cells

    著者: , , , , , , , , , - Nature Biotechnology 2003 被引用: 1,030

  15. CYP2D6-guided opioid therapy improves pain control in CYP2D6 intermediate and poor metabolizers: a pragmatic clinical trial

    著者: , , , , , , , , , , , , , , , , , , , - Genetics in Medicine 2019 被引用: 155

  16. Impact of the CYP2C19*17 Allele on Outcomes in Patients Receiving Genotype‐Guided Antiplatelet Therapy After Percutaneous Coronary Intervention

    著者: , , , , , , , , , , , , , , , , , , , , , , , , - Clinical Pharmacology & Therapeutics 2020 被引用: 50

  17. Cost-effectiveness of CYP2C19-guided antiplatelet therapy in patients with acute coronary syndrome and percutaneous coronary intervention informed by real-world data

    著者: , , , , , , , , , , , , , , , , , , - The Pharmacogenomics Journal 2020 被引用: 44

  18. Impact of the ABCD‐GENE Score on Clopidogrel Clinical Effectiveness after PCI: A Multi‐Site, Real‐World Investigation

    著者: , , , , , , , , , , , , , , , , , , , , , - Clinical Pharmacology & Therapeutics 2022 被引用: 24

  19. Loci associated with ischaemic stroke and its subtypes (SiGN): a genome-wide association study

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Lisa Cloonan, John W. Cole, Ioana Cotlarciuc, Carlos Cruchaga, Elisa Cuadrado‐Godia, Tushar Dave, Jesse Dawson, Stéphanie Debette, Hossein Delavaran, Cameron Dell, Martin Dichgans, Kimberly F. Doheny, Chuanhui Dong, David Duggan, Gunnar Engström, Michele K. Evans, Xavier Estivill Pallejà, Jessica D. Faul, Israel Fernández‐Cadenas, Myriam Fornage, Philippe M. Frossard, Karen L. Furie, Dale M. Gamble, Christian Gieger, Anne‐Katrin Giese, Eva Giralt‐Steinhauer, Hector M. González, An Goris, Sólveig Grétarsdóttir, Raji P. Grewal, Ulrike Grittner, Stefan Gustafsson, Buhm Han, Graeme J. Hankey, Laura Heitsch, Peter Higgins, Marc C. Hochberg, Elizabeth Holliday, Jemma C. Hopewell, Richard B. Horenstein, George Howard, M. Arfan Ikram, Andreea Ilinca, Erik Ingelsson, Marguerite R. Irvin, Rebecca D. Jackson, Christina Jern, Jordi Jiménez Conde, Julie A. Johnson, Katarina Jood, Muhammad S Kahn, Robert C. Kaplan, L. Jaap Kappelle, Sharon L.R. Kardia, Keith L. Keene, Brett Kissela, Dawn Kleindorfer, Simon A. Koblar, Daniel Labovitz, Lenore J. Launer, Cathy C. Laurie, Cecelia Laurie, Cue Hyunkyu Lee, Jin‐Moo Lee, Manuel Lehm, Robin Lemmens, Christopher Levi, Didier Leys, Arne Lindgren, W. T. Longstreth ほか 137 名 - The Lancet Neurology 2015 被引用: 261

  20. Hypertension pharmacogenomics: in search of personalized treatment approaches

    著者: , - Nature Reviews Nephrology 2015 被引用: 110

  21. Challenges and lessons learned from clinical pharmacogenetic implementation of multiple gene–drug pairs across ambulatory care settings

    著者: , , , , , , , , , , , , , , , , , , , , , - Genetics in Medicine 2019 被引用: 78

  22. Genetic variants associated with warfarin dose in African-American individuals: a genome-wide association study

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , James K. Burmester, Mia Wadelius, Panos Deloukas, Michael J. Wagner, Taisei Mushiroda, Michiaki Kubo, Dan M. Roden, Nancy J. Cox, Russ B. Altman, Teri E. Klein, Yusuke Nakamura, Julie A. Johnson - The Lancet 2013 被引用: 276

  23. Ethnic Differences in Cardiovascular Drug Response

    著者: - Circulation 2008 被引用: 220

  24. The Pharmacogenomics Research Network Translational Pharmacogenetics Program: Overcoming Challenges of Real-World Implementation

    著者: , , , , , , , , , - Clinical Pharmacology & Therapeutics 2013 被引用: 191